Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heaprin therapy

Canadian Journal of Hospital Pharmacy

Volumn 55, Issue 1, 2002, Pages 15-19

  Rosenbloom, David ^a   Ginsberg, Jeffrey S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti factor Xa; Low molecular weight heparin; Monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ANTIBODY DETECTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; EPIDEMIOLOGY; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 0036200661     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Drug treatment of epilepsy: A review
2. A critical reevaluation of the "therapeutic range" of aminoglycosides
3. The heparin-antithrombin system: A natural anticoagulant mechanism
4. Low-molecular weight heparins
5. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood
6. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
7. Tissue factor pathway inhibitor
8. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa
9. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma
10. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides
11. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
12. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)
13. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study
14. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin
15. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-Ha activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis
16. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery
17. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin® (LMWH) or unfractionated heparin
18. Grades of recommendation for antithrombotic drugs
19. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
20. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
21. Optimal therapeutic level of heparin therapy in patients with venous thrombosis
22. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis